Every week we highlight a company leading the charge in transparency and making waves in their industry. This week we are featuring OncoPrecision.
Founded in 2020 by Tarek Ali Zaki, Gastón Soria, Candelaria Llorens de los Ríos, and Gerardo Gatti, OncoPrecision is on a mission to increase the success of cancer therapies. In a reality where up to 75% of patients don’t respond to prescribed treatments, OncoPrecision uses patient micro avatar technology to help improve the accuracy and speed of treatments. The therapeutic platform screens potential therapies ex-vivo in under 10 days. It significantly decreases the time length compared to organoid methods currently employed.
With offices in New York and Cordoba, Argentina, this 30+ team is comprised of expert biotech and clinical researchers, data scientists, lab analysts, cell biologists, and more. What stemmed from Dr. Gastón Soria’s Synthetic Lethality in Cancer Lab has turned into a $3.3 million company, according to its last seed funding round in 2022. OncoPrecision’s continued aim is to treat patients right the first time by matching antibody-drug conjugates (ADCs) and bispecific antibodies to urgent unmet needs within the oncology field.
Do you want to be featured as “Org of the Week” in the future? Make sure to join your company and get verified!
In this article
The ORG helps
you hire great
candidates
Free to use – try today